Atossa offers shareholders a share of a priority review voucher it has yet to win

Atossa Therapeutics has given its shareholders a possible stake in an asset the company does not hold. On 8 October 2026 it entered a stapled contingent value rights agreement under which investors would receive 25% of net proceeds from selling its first FDA priority review voucher, with total payments capped at $50m.

The company has not been awarded a voucher. Any payout therefore depends on two future events: an FDA award, then a sale. At this stage there are no proceeds to distribute, and the filing facts give no indication of when or whether either step might happen.

For context, a priority review voucher entitles its holder to a faster FDA review of a later marketing application. Holders can sell vouchers to other companies, and eligibility depends on the criteria of the specific programme under which one is granted.

Alongside the rights agreement, Atossa reported operating expenses of $5.9m for the quarter ended 30 September 2026, down from $9.3m a year earlier, a fall of roughly 37%. The company's update did not, in the material reviewed, break down that decline.

Atossa also laid out its timetable for (Z)-endoxifen. It expects the FDA to clear investigational new drug applications for Duchenne muscular dystrophy and McCune-Albright syndrome by early 2027. Topline data from its Phase 2 EVANGELINE study in breast cancer are expected in the second quarter of 2027.